WO2013109209A1 - Formulations en poudre sèche comprenant de la fluticasone - Google Patents

Formulations en poudre sèche comprenant de la fluticasone Download PDF

Info

Publication number
WO2013109209A1
WO2013109209A1 PCT/TR2013/000021 TR2013000021W WO2013109209A1 WO 2013109209 A1 WO2013109209 A1 WO 2013109209A1 TR 2013000021 W TR2013000021 W TR 2013000021W WO 2013109209 A1 WO2013109209 A1 WO 2013109209A1
Authority
WO
WIPO (PCT)
Prior art keywords
range
pharmaceutical formulation
formulation according
excipient
particle size
Prior art date
Application number
PCT/TR2013/000021
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013109209A1 publication Critical patent/WO2013109209A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Definitions

  • the present invention relates to pharmaceutical formulations in dry powder form comprising fluticasone or pharmaceutically acceptable derivatives thereof in order to be used in symptomatic and/or prophylactic treatment of respiratory tract diseases, particularly asthma and COPD.
  • Fluticasone is used in the treatment of respiratory tract diseases such as asthma and COPD.
  • Fluticasone which has the chemical name of S-(fluoromethyl) (65,85,9#, 105,1 IS, 135,145, 16R, 17i?)-6,9-difluoro- 11,17-dihydroxy- 10,13,16-trimethyl-3 - oxo-6,7,8, 11, 12,14,15, 16-octahydrocyclopenta[a]phenanthrene-17-carbothioate belongs to the group of corticosteroids. Fluticasone was first disclosed in the patent numbered US4335121.
  • Corticosteroids used in the treatment of respiratory tract diseases such as asthma and COPD are synthetic and potent anti-inflammatory drugs similar to natural corticosteroid hormones secreted by adrenal glands. It is known that corticosteroids are quite effective drugs in asthma treatment. Fluticasone is a molecule which belongs to said group.
  • the dry powder formulation comprising fluticasone has good flow characteristics is an important criterion in terms of inhalation of said formulation effectively and therefore in terms of providing an effective treatment.
  • a dry powder formulation which does not have good flow characteristics is obtained, it is seen that the formulation has low homogeneity and consequently dosing accuracy cannot be ensured during filling the dry powder formulation prepared into reservoirs of multi dose inhalators comprising more than one dose or into blister cavities of a blister package, each of them comprising one dose, or into capsules comprising one dose.
  • the fact that the dry powder formulation does not have good flow characteristics affects emptying capacity and emptying attribute negatively during inhalation of the formulation from capsule, blister or reservoir.
  • the active agent cannot reach to the lungs in sufficient amounts.
  • the active agent is diluted by various non-functional excipients.
  • the physical characteristics of these excipients, used in quite high amounts as compared to the active agent amount in the formulations, such as average particle size have an important role in providing good flow in the dry powder formulation. Since the active agent used is delivered to the lungs in a sufficient amount and in a controlled manner in the dry powder formulation having good flow characteristics, desired therapeutic effect is obtained.
  • the inventors have developed dry powder formulations which comprise fluticasone and/or pharmaceutically acceptable derivatives thereof and have high homogeneity and good flow characteristics wherein dose uniformity is ensured and sufficient amount of active agent can be delivered to the lungs.
  • the present invention relates to pharmaceutical formulations in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof.
  • dry powder formulations comprising fluticasone in the range of 20 to 800 ⁇ g, preferably in the range of 25 to 600 ⁇ g and also at least one pharmaceutically acceptable fine grained and coarse grained excipient having an average particle size ratio to each other in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 :10 have good flow characteristics and high homogeneous dispersion, therefore dose uniformity is obtained in the formulations and sufficient amount of active agent can be delivered to the lungs.
  • the fine grained excipient used in the text refers to an excipient having an average particle size less than 10 ⁇ , preferably in the range of 0.1 to 9.9 ⁇ , more preferably in the range of 2 to 8 ⁇ ⁇ , for instance in the range of 0.3, 0.5, 0.7, 0.9, 1.1, 1.3, 1.5, 1.7, 1.9, 2.3, 2.5, 3.0, 3.5, 4.0, 4.5 to 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 ⁇ ;
  • the coarse grained excipient used in the text refers to an excipient having an average particle size in the range of 10 to 90 ⁇ , preferably in the range of 12 to 85 ⁇ , more preferably in the range of 15 to 80 ⁇ , for instance in the range of 15, 20, 25, 30, 35, 40, 45 to 50, 55, 60, 65, 70, 75, 80, 85 ⁇ .
  • the subject of the present invention is the pharmaceutical formulation in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof, characterized in that - the amount of fluticasone in said formulation is in the range of 20 to 800 ⁇ g, preferably in the range of 25 to 600 ⁇ ,
  • the excipient comprised in said formulation is composed of at least one pharmaceutically acceptable excipient mixture comprising fine grained excipient and coarse grained excipient and
  • the average particle size ratio of the fine grained excipient to the coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 : 15 to 1 : 10.
  • the active agent fluticasone and/or pharmaceutically acceptable derivatives thereof comprised in the dry powder drug formulation of the present invention comprise fluticasone's free base, pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms and/or a combination thereof.
  • the inhalation formulation comprising fluticasone and/or pharmaceutically acceptable derivatives thereof can be delivered to the patient in dry powder form.
  • Said dry powder formulations further comprise at least one physiologically and pharmaceutically acceptable excipient along with the active agent.
  • This excipient is composed of fine grained excipient, coarse grained excipient or a combination thereof, preferably a combination of fine grained excipient and coarse grained excipient.
  • This excipient can be selected from monosaccharides (glucose etc.), disaccharides (lactose, saccharose, maltose or pharmaceutically acceptable hydrates, anhydrates or a combination thereof etc.), oligosaccharides and polysaccharides (dextrant etc.), polyalcohols (sorbitol, mannitol, xylitol etc.), salts (sodium chloride, calcium carbonate etc.) or a combination thereof. Same or different substances are used as fine grained excipient and coarse grained excipient, though preferably the same substance is used. Fine grained and coarse grained excipients are preferably lactose, more preferably lactose anhydrate. According to the present invention, the amount of the pharmaceutically acceptable excipient is preferably in the range of 1-50 mg, preferably in the range of 2-40 mg, more preferably in the range of 3-30 mg.
  • the average particle size of the active agent used is quite important in order that the formulation to be obtained has good flow characteristics and therefore an effective inhalation is performed.
  • the inventors have seen that use of an active agent having an average particle size in the range of 1 ⁇ to 10 ⁇ , preferably in the range of 1.5 ⁇ to 7.5 ⁇ , more preferably in the range of 1.5 ⁇ ⁇ to 5 ⁇ has a significant contribution to the formulation obtained for having proper flow characteristics and for having dose uniformity and to delivery of the active agent to the lungs in sufficient amount.
  • the dose of the drug which is delivered to the lungs is also an important parameter in order to provide an effective inhalation treatment.
  • the Fine particle fraction (FPF) value of the drug particles are measured.
  • the inventors have observed that when fluticasone used as active agent has an average particle size in the range of 1 ⁇ to 10 ⁇ , preferably in the range of 1.5 ⁇ to 7.5 ⁇ , more preferably 1.5 ⁇ to 5 ⁇ , FPF (fine particle fraction) value of the formulation is in the range of 1-20%, preferably % 2-15 indicating high deposition of the drug particles in the lung.
  • the subject of the present invention is pharmaceutical formulations in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof, characterized in that
  • the amount of fluticasone in said formulation is in the range of 20 to 800 ⁇ g, preferably in the range of 25 to 600 ⁇ g,
  • the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 :10 and
  • the average particle size of the active agent used is in the range of 1 ⁇ to 10 ⁇ , preferably in the range of 1.5 ⁇ to 7.5 ⁇ , more preferably in the range of 1.5 ⁇ to 5 ⁇ .
  • the particle size of the bulk formulation is also important for the flowability and dose uniformity of the formulation.
  • the inventors have seen that when the average particle size of the bulk formulation is in the range of 10-200 um, preferably 25-150 ⁇ and more preferably 45- 125 ⁇ , flowability of the bulk formulation is increased during the production and a homogeneous dry powder formulation which has a high dose uniformity is obtained.
  • the present invention relates to the pharmaceutical formulations in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof wherein the average particle size of the bulk formulation is in the range of 10-200 ⁇ , preferably 25-150 ⁇ and more preferably 45- 125 ⁇ .
  • bulk formulation used herein signifies the total formulation obtained by mixing the active agent and the excipients during the production.
  • the amounts of said fine grained and coarse grained excipients constituting the excipient combination having two different average particle sizes as fine grained and coarse grained comprised in the dry powder formulation of the present invention is an important criterion in obtaining the characteristics that can provide an effective treatment.
  • the inventors have seen that characteristics such as proper flow, particularly homogenous particle dispersion and dose uniformity of the formulation are ensured and therefore the sufficient amount of the active agent reaches to the lungs more easily in the case that the ratio of fine grained excipient to coarse grained excipient constituting the excipient combination is in the range of 1 :1 to 1 :25 by weight, preferably in the range of 1 : 1 to 1 : 10 by weight, more preferably in the range of 1 : 1.5 to 1 :5 by weight.
  • the subject of the present invention is the pharmaceutical formulations in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof, characterized in that the amount of fluticasone in said formulation is in the range of 20 to 800 ⁇ g, preferably in the range of 25 to 600 ⁇ g,
  • the average particle size ratio of fine grained excipient: coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 :15 to 1 :10 and
  • the ratio of fine grained excipient to coarse grained excipient is in the range of 1 : 1 to 1 :25 by weight, preferably in the range of 1 :1 to 1 : 10 by weight, more preferably in the range of 1 : 1.5 to 1 :5 by weight.
  • the inventors have observed that that the weight ratio of the fluticasone active agent to the fine grained excipient and coarse grained excipient affects on providing proper flow, homogenous particle dispersion and dose uniformity of the formulation. They have seen that when the ratio of fluticasone active agent to the fine grained excipient is in the range of 1 :1- 1 :25, preferably 1 :5- 1 :20 by weight and the ratio of fluticasone active agent to the coarse grained excipient is in the range of 1 :1- 1 :80, preferably 1 :30- 1 :70 by weight, a homogenous particle dispersion and dose uniformity of the formulation are provided so that the sufficient amount of the active agent reaches to the lungs more easily.
  • the present invention relates to the pharmaceutical formulations in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof wherein the ratio of fluticasone active agent to the fine grained excipient is in the range of 1 : 1 - 1 :25, preferably 1 :5- 1 :20 by weight and the ratio of fluticasone active agent to the coarse grained excipient is in the range of 1 : 10- 1 :80, preferably 1 :30- 1 :75 by weight.
  • the present invention relates to the pharmaceutical formulations in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof wherein the ratio of bulk density to tapped density is in the range of of 1 : 10 to 9:10, preferably 3:10 to 8:10.
  • the tapped density is obtained by compacting the bulk density with vibrational motion.
  • the process for preparation of the pharmaceutical formulations of the present invention in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof is composed of the following steps:
  • the present invention relates to inhalation of the dry powder formulations comprising fluticasone and/or pharmaceutically acceptable derivatives thereof by using inhalation devices comprising capsule, blister or reservoir.
  • the inventors have found that the inhalation is performed most productively when capsule volume comprising the drug in dry powder form of the present invention comprising fluticasone and/or pharmaceutically acceptable derivatives thereof is in the range of 0.1 to 0.5 ml, preferably in the range of 0.15-0.45 ml, more preferably in the range of 0.2-0.4 ml.
  • the present invention is characterized in that volume of the capsule used for storage and delivery of the drug in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof is in the range of 0.1 to 0.5 ml, preferably in the range of 0.15-0.45 ml, more preferably in the range of 0.2-0.4 ml.
  • the inventors have seen that the active agent comprised in the capsule is protected from external factors as well as the possibility of moistening that can arise from the nature of the capsule itself is removed in the case that moisture ratio of the package in capsule form having high protection property against moisture and other negative external factors is in the range of 5-20%, preferably in the range of 7-15%.
  • moisture ratio of the package in capsule form having high protection property against moisture and other negative external factors is in the range of 5-20%, preferably in the range of 7-15%.
  • the present invention is characterized in that moisture ratio of the package in capsule form used for storage and delivery of the drug in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof is in the range of 5-20%, preferably in the range of 7-15%.
  • the capsule preferred to be used in the scope of the present invention can be made of a substance selected from a group comprising gelatine, chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers, and it is composed of telescoping body and cap parts.
  • capsule material in the case that the dry powder formulation of the present invention is inhaled from capsule, capsule material can be selected from a group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose if the capsule to be used is made of cellulose and its derivatives.
  • capsule material can be selected from a group comprising polyethylene, polyester, polyethyleneterephthalate, polycarbonate or polypropylene if the capsule to be used is made of synthetic polymer.
  • various molecular weighted polyethylene glycol, sorbitol, glycerol, propylene glycol, polyethylene oxide-propylene oxide block copolymers and/or other polyalcohols and polyethers can be added as adjuvant if the capsule material to be used is made of gelatine.
  • the inventors have found that in the case that fullness ratio of the capsule cavity used is in the range of 0.05 to 25 %, preferably in the range of 0.1 to 20%, more preferably in the range of 0.5-15%, an effective inhalation of the drug is ensured in the case that said dry powder formulation is inhaled from capsule.
  • the present invention is characterized in that fullness ratio of capsule cavity is in the range of 0.05 to 25%, preferably in the range of 0.1 to 20%, more preferably in the range of 0.5 to 15%.
  • the dry powder formulation of the present invention is inhaled from blister, which is one of the inhalation methods
  • the inventors have found that an effective inhalation is performed in the case that cavity volume of the blister comprising the drug in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof is in the range of 18-30 mm 3 , preferably in the range of 20 - 25 mm 3 , more preferably in the range of 21-24 mm 3 .
  • the present invention is characterized in that cavity volume of the blister used for storage and delivery of the drug in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof is in the range of 18-30 mm 3 , preferably in the range of 20 to 25 mm 3 , more preferably in the range of 21-24 mm 3 in the case that said dry powder formulation is inhaled from blister.
  • fullness ratio of the blister cavity used should be in the range of 15-95%, preferably in the range of 20-85% and more preferably in the range of 50-80% in order to inhale the formulation of the present invention from blister without any problem and in order to perform an effective inhalation.
  • the present invention is characterized in that fullness ratio of the blister used for storage and delivery of the drug in dry powder form comprising fluticasone and/or pharmaceutically acceptable derivatives thereof is in the range of 15-95%, preferably in the range of 20-85% and more preferably in the range of 50- 80%.
  • the base and the lid sheets constituting the peelable blister strip pack, wherein the blisters comprising the dry powder formulation of the present invention are collocated are sealed tightly by any suitable method in order to provide impermeability.
  • the base and lid sheets constituting the peelable blister strip package comprising the dry powder formulation of the present invention are composed of many layers. Polymeric layers, aluminium foil and preferably Aclar® fluoropolymer film are among the layers constituting the base and the lid sheets.
  • Desiccant agents added to the layers constituting blister strip package comprising dry powder formulation of the present invention are selected from silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated carbon, hydrophilic chyles.
  • polymeric layers in the base and lid sheets of peelable blister strip package comprising said dry powder formulation are made of the same or different polymers. Thickness of these polymeric layers varies depending on- the type and characteristics of the polymeric material used. Therefore, thickness of polymeric layer varies in the range of 15-55 ⁇ , preferably in the range of 20-30 ⁇ according to the type of the polymeric material used.
  • the layer covering the inner surface of the cavity is a polymeric layer because of the fact that when the layer in contact with the dry powder formulation in the blister cavity is aluminium foil, some part of dry powder formulation adheres to the inner surface of the blister cavity due to porous structure of the aluminium foil and electrostatic forces and this causes uncontrolled dose inhalation.
  • Polymers constituting the polymeric layer can preferably be selected from thermoplastic polymers such as polyethylene, polypropylene, polystyrene, polyolefin, polyamide, polyvinyl chloride, polyurethane or synthetic polymers.
  • the drug composition in dry powder form described in the present invention comprising fluticasone and/or pharmaceutically acceptable derivatives thereof can be used in the treatment of many respiratory diseases particularly asthma, Chronic Obstructive Pulmonary Disease (COPD) and allergic rhinitis.
  • the drug composition of the present invention is used in the treatment of respiratory tract diseases comprising, but not limited to, allergic or non allergic asthma in every stage, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airways hyperactivity, chronic obstructive pulmonary disease including bronchiectasis, emphysema and chronic bronchitis; airways or lung diseases (COPD, COAD or COLD) pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.
  • This treatment may be prophylactic or symptomatic.
  • the composition of the present invention
  • EXAMPLE 1 Inhalation of dry powder formulations comprising fluticasone from capsule
  • fine grained lactose and coarse grained lactose are stirred in a mixer after sieved separately. Fluticasone is added into this mixture, sieved again and stirred. The powder mixture obtained at the end of the process is filled into capsules.
  • EXAMPLE 2 Inhalation of dry powder formulations comprising fluticasone from capsule
  • fine grained lactose and coarse grained lactose are stirred in a mixer after sieved separately. Fluticasone is added into this mixture, sieved again and stirred. The powder mixture obtained at the end of the process is filled into capsules.

Abstract

La présente invention concerne des formulations pharmaceutiques en poudre sèche comprenant de la fluticasone, utilisables dans le traitement de maladies des voies respiratoires.
PCT/TR2013/000021 2012-01-16 2013-01-16 Formulations en poudre sèche comprenant de la fluticasone WO2013109209A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/00487 2012-01-16
TR201200487 2012-01-16

Publications (1)

Publication Number Publication Date
WO2013109209A1 true WO2013109209A1 (fr) 2013-07-25

Family

ID=47913531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000021 WO2013109209A1 (fr) 2012-01-16 2013-01-16 Formulations en poudre sèche comprenant de la fluticasone

Country Status (1)

Country Link
WO (1) WO2013109209A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093820A2 (fr) * 2010-01-28 2011-08-04 Mahmut Bilgic Composition pharmaceutique combinée comprenant du tiotropium
US20110262543A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. Process for providing particles with reduced electrostatic charges

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093820A2 (fr) * 2010-01-28 2011-08-04 Mahmut Bilgic Composition pharmaceutique combinée comprenant du tiotropium
US20110262543A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. Process for providing particles with reduced electrostatic charges

Similar Documents

Publication Publication Date Title
EP2528585B1 (fr) Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide
EP2528596B1 (fr) Composition sous forme de poudre sèche pour administration par inhalation comprenant une combinaison de bromure de tiotropium, de xynafoate de salmeterol et de propionate de fluticasone.
EP2533777B1 (fr) Compositions pharmaceutiques contenant de la fluticasone, du tiotropium et du cromoglycate de sodium
EP2528600B1 (fr) Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone
WO2011093819A2 (fr) Nouvelle composition pharmaceutique combinée comprenant du tiotropium
WO2011093820A2 (fr) Composition pharmaceutique combinée comprenant du tiotropium
WO2013109210A1 (fr) Formulations en poudre sèche comprenant du budésonide
EP2480203B1 (fr) Formulation de poudre sèche de tiotropium contenue dans une bande alvéolée thermoformée
WO2013109220A1 (fr) Formulations en poudre sèche comprenant du tiotropium, du formotérol et du budésonide
WO2013009271A1 (fr) Nouvelle formulation améliorée de poudre sèche
WO2013109219A1 (fr) Formulations en poudre sèche comprenant du tiotropium et du carmotérol
EP2804584A1 (fr) Formulations en poudre sèche comprenant du carmotérol et de la ciclésonide
EP2804589A1 (fr) Formulations pharmaceutiques comprenant de l'aztréonam
WO2013109209A1 (fr) Formulations en poudre sèche comprenant de la fluticasone
WO2011093811A2 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
EP2528597B1 (fr) Composition sous form de poudre sèche comprenant une combinaison de bromure de tiotropium, fumarate de formoterol et de furoate de mometasone
WO2013109212A1 (fr) Formulations en poudre sèche comprenant de la ciclésonide
WO2013109207A1 (fr) Formulations de poudre sèche comprenant de la mométasone
EP2480202B1 (fr) Bande alvéolée thermoformée contenant une combinaison qui renferme du tiotropium
EP2515888B1 (fr) Poudre sèche pour inhalation comprenant tiotropium
WO2013109213A2 (fr) Formulations pharmaceutiques comprenant du tiotropium
WO2013109208A1 (fr) Formulations comprenant du formotérol utilisé comme agent actif
EP2804583A1 (fr) Formulations en poudre sèche comprenant du r-formotérol utilisé comme agent actif
WO2011093812A2 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
WO2011078816A1 (fr) Combinaison de poudres sèches de tiotropium, de formotérol et d'un dérivé d'acide cromoglycique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13711158

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13711158

Country of ref document: EP

Kind code of ref document: A1